Corcept Therapeutics (NASDAQ:CORT) is one of the 17 biotechnology stocks with more than 50% upside. On February 2, Edward Nash from Canaccord Genuity reaffirmed his Buy rating for Corcept Therapeutics …
FDA-issued CRL for relacorilant NDA leads to bullish views around Corcept Therapeutics (CORT)
view original post